Fundraising FoxProto Axiom — Full Portfolio
9 tracked investments · listed companies and verified rows first
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPSanofi VenturesSV Health InvestorsTenmileAbingworth+2 more
Floaxiom develops NanoSurface, a biologically manufactured affinity nanoparticle platform for antibody (mAb) purification, offering a chromatography-free alternative to protein A resin columns and membrane systems.
BiotechDeep TechNew Materials
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amazing GutCellutechEndo AxiomHerikinJumpStart FertilityOnyx AxiomSWAN Genomics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.